SiRe run metric parameters in relation to sample characteristics
| Patients (n=294) | Clinical characteristics n | Average reads per sample n | Mean number of mapped reads per sample | Median read length bp | Percentage reads on targets % | Average reads per amplicon n | Uniformity of coverage % |
| Sample Type | Cytology (n=164) | 179 674.38 | 178 577.14 | 131.24 | 95.53 | 4158.16 | 97.61 |
| Histology (n=130) | 149 217.18 | 147 739.80 | 129.88 | 97.11 | 3382.14 | 98.01 | |
| Site | Primary (n=214) | 173 895.56 | 172 487.57 | 130.71 | 96.21 | 3998.57 | 97.83 |
| Metastasis (n=80) | 145 639.78 | 144 756.08 | 130.44 | 96.28 | 3313.46 | 97.68 | |
| Diagnosis | ADC (n=168) | 167 496.93 | 165 950.43 | 129.89 | 95.42 | 3837.92 | 98.20 |
| Favour ADC (n=92) | 173 212.78 | 172 301.83 | 132.16 | 97.62 | 4000.08 | 97.42 | |
| NEC (n=4) | 106 203.75 | 105 720.50 | 130.25 | 96.86 | 2019.23 | 98.61 | |
| NOS (n=24) | 147 817.54 | 147 005.04 | 130.83 | 96.32 | 3400.36 | 96.51 | |
| SqCC (n=6) | 136 224.00 | 135 063.67 | 127.50 | 96.86 | 3138.93 | 96.52 | |
| %NC | 5–25 (n=84) | 171 959.93 | 172 067.95 | 130.88 | 94.65 | 3992.09 | 97.84 |
| 26–50 (n=94) | 184 656.17 | 181 700.28 | 131.12 | 97.23 | 4192.93 | 98.28 | |
| >50 (n=116) | 147 090.67 | 146 200.78 | 130.07 | 96.56 | 3373.80 | 97.35 |
ADC, adenocarcinoma; bp, base pairs; %NC, neoplastic cell percentage; NEC, neuroendocrine carcinoma; SqCC, squamous cell carcinoma.